Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brodalumab Extension Study in Psoriasis and Psoriatic Arthritis
NCT04183881Phase 4Completed
- Sponsor
- Kyowa Kirin
- Start
- Jul 2016
- Primary completion
- Jan 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of brodalumab in Psoriasis vulgaris (PV), psoriatic arthritis (PsA), pustular psoriasis and 2 more, sponsored by Kyowa Kirin. Primary endpoints: Incidence and types of adverse events and adverse reactions at 28 weeks and Anti-KHK4827 antibody at 28 weeks. Started Jul 2016; status: completed.
02
Drugs
brodalumab
03
Conditions
Psoriasis vulgaris (PV)psoriatic arthritis (PsA)pustular psoriasiserythrodermic psoriasisPalmoplantar psoriasis (PPP)
Beyond the preview
Go deeper on NCT04183881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04183881.